Peptides Semax and Selank Modulate Behavior in Parkinson's Rat Model
Background
Parkinson's disease (PD) is a severe, progressive neurodegenerative disorder characterized by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) region of the brain, leading to motor and non-motor symptoms. While current treatments primarily target motor symptoms, non-motor aspects like anxiety significantly impact patient quality of life. This study addresses the knowledge gap of how the synthetic regulatory peptides Semax and Selank affect behavioral symptoms, specifically anxiety and motor activity, in an animal model of PD-like parkinsonism.
Results
The study revealed that neither Semax nor Selank had a significant impact on the general motor activity of the rats in an elevated cross-shaped maze, nor did they affect passive defensive behavior. However, a key finding emerged regarding anxiety: Selank notably decreased the level of anxiety in rats suffering from toxic damage to their dopaminergic (DA) neurons. This anxiolytic effect of Selank was consistent with prior research showing similar benefits in healthy rodents exposed to various psycho-emotional stressors. This suggests that the toxic damage to the substantia nigra did not impede the rat organism's response to Selank's anxiety-reducing properties. Selank significantly decreased the level of anxiety in rats with 6-OHDA induced dopaminergic (DA) neuron damage, demonstrating a consistent anxiolytic effect even in the presence of neurodegeneration.
Why It Matters
This research highlights the potential of Selank as a therapeutic agent for managing non-motor symptoms, specifically anxiety, in Parkinson's disease, even in the presence of significant neurodegeneration. The fact that its anxiolytic effect persists despite dopaminergic neuron damage suggests a mechanism independent of direct DA system repair, potentially targeting other neurotransmitter systems or pathways involved in stress response. This finding suggests Selank could be a valuable candidate for clinical development to alleviate anxiety in Parkinson's patients. Future research should focus on elucidating the precise molecular mechanisms, conducting dose-response studies, and eventually progressing to human clinical trials (Phase II and III) to confirm these benefits.